Contrasting this, IHC 3 + BC patients the association between longer survival and anti-HER2 therapy was observed in both ER- and ER+ groups (BCSS P < 0.001 and P = 0.005, for ER- and ER + , respectively). The gene discussed is ESR1; the disease is breast cancer.